16-Oct-2026 14:08:07
CORRECTION: SOLARA ACTIVE PHARMA Q2 FY27 ; NET PROFIT AT ₹28.50 CR VS LOSS OF ₹10.10 CR (YOY), UP 75% (QOQ)
REVENUE UP 33% AT ₹417.30 CR (YOY), UP 9% (QOQ) EBITDA UP 121% AT ₹77 CR (YOY), UP 24% (QOQ) MARGINS AT 18.4% VS 11.1% (YOY), 16.2% (QOQ)